Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc., a Delaware corporation, on September 11, 2026. The company is an emerging growth company with its principal executive offices in San Antonio, Texas. Its common stock and warrants trade on the Nasdaq Capital Market under the symbols BIAF and BIAFW, respectively.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of presentation materials rather than a financial results announcement.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing solely discloses the preparation of presentation materials intended for use at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14–16, 2026.
Guidance, Outlook, and Risks
Management intends to use the attached presentation materials (Exhibit 99.1) to discuss the company's operations and performance. The filing explicitly states that the information contained in Item 7.01 and Exhibit 99.1 is furnished and not "filed" for purposes of Section 18 of the Exchange Act. Consequently, this information is not subject to the liabilities of that section and shall not be incorporated by reference into any other filings under the Securities Act or the Exchange Act.
Key Facts for Investor Verification
- Verify the content of the "Presentation Materials" attached as Exhibit 99.1 for specific operational updates or forward-looking statements.
- Confirm that the presentation materials are not legally "filed" and therefore do not carry the same liability protections as standard SEC filings.
- Note the upcoming conference dates (September 14–16, 2026) where management will present these materials.
- Check subsequent filings for actual financial data, as this 8-K contains no quantitative financial metrics.